Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/09612033231210398 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced Therapies in Elderly Patients With Inflammatory Bowel Disease: A Comparative Retrospective Cohort Study in Taiwan.
Ther Clin Risk Manag
April 2025
School of Medicine, Chang Gung University, Taoyuan City, Taiwan.
Purpose: Inflammatory Bowel Disease (IBD) predominantly affects younger individuals, but emerging data indicates a shift toward older populations. Elderly-onset IBD (diagnosed at 60 years or older) differs from younger-onset IBD, presenting with atypical symptoms and higher risks of infections and malignancies. However, drug persistence is underexplored in the elderly IBD group, warranting further investigation to optimize treatment strategies for this demographic.
View Article and Find Full Text PDFInsulin sensitivity in moderately severe to acute severe ulcerative colitis.
Scand J Gastroenterol
March 2025
Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Background: Patients hospitalized with moderately severe or acute severe ulcerative colitis (UC) may experience metabolic disturbances, including alterations in insulin resistance due to inflammation and the administration of glucocorticoids (GCs). This pilot study aimed to evaluate insulin sensitivity in patients hospitalized for moderately severe to severe UC.
Method: Patients hospitalized for moderately-severely active UC at Örebro University Hospital, Sweden, were eligible for inclusion.
[Treatment of severe flares in Crohn's disease and ulcerative colitis].
Inn Med (Heidelb)
January 2025
Abteilung für interventionelle gastroenterologische Endoskopie, Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen, Deutschland.
Background: In chronic inflammatory bowel diseases (IBD), severe flares are characterized by intense inflammatory activity and a high disease burden for patients. Treatment addresses both short-term goals (e.g.
View Article and Find Full Text PDFTocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Ann Oncol
January 2025
Department of Medicine, Immunology and Allergy Service. Electronic address:
Article Synopsis
- This study evaluated the effectiveness of tocilizumab (TCZ) for treating arthritis caused by immune checkpoint inhibitors (ICI-AR) and preventing relapses during ICI treatment reassignment.
- Researchers analyzed data from 26 patients, finding that all patients treated with TCZ had significant improvement in their arthritis symptoms and many achieved remission without steroids after 24 weeks.
- The results indicated that using TCZ as a preventive measure during ICI rechallenge significantly reduced relapse rates and extended ICI treatment duration compared to patients not receiving TCZ.
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
Lancet Rheumatol
August 2024
Department of Medicine, Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, VIC, Australia.
Background: Validation of protective associations of the lupus low disease activity state (LLDAS) against flare, irreversible damage, health-related quality of life, and mortality has enabled the adoption of treat-to-target strategies in patients with systemic lupus erythematosus (SLE). Previous validation studies were of short duration, limiting the ability to detect longer term signals in flare rate and irreversible damage. In addition, previous studies have focused on percent time at target, rather than actual periods of time that are more useful in clinical practice and trials.
View Article and Find Full Text PDF